These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 20097584)

  • 21. The phantom menace of prostate cancer screening.
    Ghani KR; Trinh QD; Menon M
    BJU Int; 2012 Feb; 109(3):324-6. PubMed ID: 22243666
    [No Abstract]   [Full Text] [Related]  

  • 22. [A fair trial? The European randomized prostatic cancer study].
    Scholten HJ
    Ned Tijdschr Geneeskd; 1995 Jun; 139(25):1302-3. PubMed ID: 7541896
    [No Abstract]   [Full Text] [Related]  

  • 23. ERSPC and PLCO prostate cancer screening studies: what are the differences?
    Schröder FH; Roobol MJ
    Eur Urol; 2010 Jul; 58(1):46-52. PubMed ID: 20362385
    [No Abstract]   [Full Text] [Related]  

  • 24. Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
    Terris MK
    Eur Urol; 2009 Feb; 55(2):392; discussion 393. PubMed ID: 18353530
    [No Abstract]   [Full Text] [Related]  

  • 25. Perspective on prostate cancer screening.
    Rogers CS
    Int J Clin Pract; 2011 Jan; 65(1):31-4. PubMed ID: 21155942
    [No Abstract]   [Full Text] [Related]  

  • 26. Detection characteristics in randomized prostate screening.
    Schröder FH; Roobol MJ
    Clin Cancer Res; 2004 Sep; 10(17):5641-2. PubMed ID: 15355886
    [No Abstract]   [Full Text] [Related]  

  • 27. Validity and legacy of prostate-specific antigen (PSA) and PSA-based parameters and isoforms in the new millennium.
    Djavan B
    Eur Urol; 2010 Jun; 57(6):928-9. PubMed ID: 20304552
    [No Abstract]   [Full Text] [Related]  

  • 28. Editorial for "Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50".
    Andriole GL; Kibel AS
    Cancer; 2011 Mar; 117(6):1110-2. PubMed ID: 20960524
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
    Jackson BR
    Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
    [No Abstract]   [Full Text] [Related]  

  • 30. The case for prostate cancer screening.
    Andriole GL
    Semin Urol; 1993 May; 11(2):50-3. PubMed ID: 7689738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Early detection of prostatic carcinoma: Is PSA screening suitable?].
    Kaulen H
    Dtsch Med Wochenschr; 2003 May; 128(18):977. PubMed ID: 12755136
    [No Abstract]   [Full Text] [Related]  

  • 33. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality.
    Höltl W; Lunglmayr G
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868
    [No Abstract]   [Full Text] [Related]  

  • 34. Prostate specific antigen for detecting early prostate cancer.
    Ilic D; Green S
    BMJ; 2009 Sep; 339():b3572. PubMed ID: 19778970
    [No Abstract]   [Full Text] [Related]  

  • 35. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Screening for prostate cancer".
    Gohagan JK; Kramer BS; Greenwald P
    Am J Prev Med; 1994; 10(4):245-6. PubMed ID: 7528519
    [No Abstract]   [Full Text] [Related]  

  • 37. PSA-based screening for localised prostate cancer. Uncertain benefits, potential adverse consequences, and many outstanding questions.
    Prescrire Int; 2009 Oct; 18(103):225. PubMed ID: 19882799
    [No Abstract]   [Full Text] [Related]  

  • 38. Current status of PSA screening. Early detection of prostate cancer.
    Pickles T
    Can Fam Physician; 2004 Jan; 50():57-63. PubMed ID: 14761105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Large part of Swedish men PSA tested for early prostatic cancer. Few aware of the disadvantages of the test].
    Bratt O; Grenabo L
    Lakartidningen; 2010 Feb 17-23; 107(7):432-5. PubMed ID: 20384075
    [No Abstract]   [Full Text] [Related]  

  • 40. Prostate-specific antigen and screening for prostate cancer.
    Han M; Gann PH; Catalona WJ
    Med Clin North Am; 2004 Mar; 88(2):245-65, ix. PubMed ID: 15049577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.